TABLE 2.
Patient characteristics.
| WOEST |
PIONEER AF-PCI |
RE-DUAL PCI |
AUGUSTUS |
ENTRUST-AF PCI |
||||||||||
| VKA + P2Y12 inhibitor |
VKA + DAPT |
Rivaroxaban + P2Y12 inhibitor |
Rivaroxaban + DAPT |
VKA + DAPT |
Dabigatran + P2Y12 inhibitor |
Dabigatran + P2Y12 inhibitor |
VKA + DAPT |
Apixaban + DAPT |
Apixaban + P2Y12 inhibitor |
VKA + DAPT |
VKA + P2Y12 inhibitor |
Edoxaban + P2Y12 inhibitor |
VKA + DAPT |
|
| Sample size | 279 | 284 | 709 | 709 | 706 | 981 | 763 | 981 | 1,153 | 1,153 | 1,154 | 1,154 | 751 | 755 |
| Age | 70 | 70 | 70 | 70 | 70 | 72 | 69 | 72 | 71 | 70 | 71 | 71 | 69 | 70 |
| Male | 214 | 234 | 528 | 535 | 518 | 710 | 529 | 750 | 796 | 841 | 815 | 826 | 557 | 563 |
| Diabetes, % | 24.3 | 25.4 | 28.8 | 28.1 | 31.3 | 36.9 | 34.1 | 37.9 | 37.1 | 35.9 | 35.9 | 36.6 | 34.5 | 34.2 |
| History, % | ||||||||||||||
| MI | 34.3 | 35.2 | 19.7 | 25.4 | 22.2 | 24.2 | 25,4 | 27,3 | – | – | – | – | 25 | 23.4 |
| PCI | 30.8 | 35.6 | – | – | – | 33.3 | 31.3 | 35.4 | – | – | – | – | 25 | 23.4 |
| CABG | 20.1 | 26.1 | – | – | – | 9.9 | 10.4 | 11.3 | – | – | – | – | 6.1 | 6.5 |
| GB | 5 | 4.9 | 1 | 1.3 | 0.7 | – | – | – | – | – | – | – | – | – |
| CHA2DS2-VASc score, % | ||||||||||||||
| <3 | – | – | 26.7 | 23.7 | 20.8 | 23.4 | 32.4 | 19.7 | 20.8 | 21.5 | 20.8 | 19.1 | – | – |
| >2 | – | – | 73.3 | 76.3 | 79.2 | 76.6 | 67.6 | 80.3 | 79.2 | 78.5 | 79.2 | 80.9 | – | – |
| HAS-BLED score, % | ||||||||||||||
| <3 | – | – | 27.6 | 32 | 29.5 | 33.3 | 40.5 | 29.4 | 50.5 | 51.7 | 50.9 | 39.6 | 31.8 | 27 |
| >2 | – | – | 72.3 | 68 | 70.5 | 66.8 | 59.5 | 70.6 | 49.5 | 48.3 | 49.1 | 50.4 | 62.2 | 66.6 |
| Arterial access, % | ||||||||||||||
| Radial | 26.5 | 25 | – | – | – | 63 | 65.8 | 62.3 | – | – | – | – | 77.5 | 80.5 |
| Femoral | 73.1 | 73.2 | – | – | – | 36.6 | 33 | 36.8 | – | – | – | – | 22.4 | 19.3 |
| Stent type, % | ||||||||||||||
| None | 1.8 | 1.4 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Bare metal | 31.9 | 30.3 | 32.6 | 31.2 | 31.8 | 15.2 | 16.1 | 13.6 | – | – | – | – | – | – |
| Drug eluting | 64.9 | 64.4 | 65.4 | 66.8 | 66.5 | 82.1 | 81.5 | 84.6 | – | – | – | – | – | – |
| Both | 1.1 | 3.9 | 2 | 2.9 | 1.7 | 1.9 | 1.3 | 1.2 | – | – | – | – | – | – |
| Other | – | – | – | – | – | 0.8 | 1 | 0.5 | – | – | – | – | – | – |
| Creatinine clearance, mL/min/1.73 m2 | – | – | 78.3 | 77.5 | 80.7 | 76.3 | 83.7 | 75.4 | 78.5 | 79.4 | 78.7 | 80 | 71.8 | 71.7 |
| Type of index event, % | ||||||||||||||
| NSTEMI | – | – | 18.5 | 18.3 | 17.8 | 20.7 | 23.5 | 21 | – | – | – | – | 21.7 | 20.8 |
| STEMI | – | – | 12.3 | 13.8 | 10.7 | 14.7 | 14.9 | 14.6 | – | – | – | – | 17.7 | 17.5 |
| UA | – | – | 20.7 | 21.1 | 23.7 | 19.9 | 16.5 | 16.9 | – | – | – | – | 14.9 | 16.3 |
| Type of AF | ||||||||||||||
| Persistent | – | – | 20.7 | 20.6 | 21.1 | 17.7 | 17.3 | 18.2 | – | – | – | – | 18.6 | 19.3 |
| Permanent | – | – | 37.4 | 33.6 | 34.5 | 32.6 | 32.8 | 32.4 | – | – | – | – | 27.8 | 33.1 |
| Paroxysmal | – | – | 42.8 | 46.1 | 44.4 | 49.6 | 49.8 | 49.4 | – | – | – | – | 53.5 | 47.4 |
VKA, vitamin K antagonists; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; GB, gastrointestinal bleeding; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; UA, unstable angina; AF, atrial fibrillation.